Wegovy for Teens: What Parents and Young People Should Know

Your teenager has been struggling with their weight and you've heard about Wegovy, here's the honest answer

You've probably seen news stories about GLP-1 medicines transforming adult weight loss, and it's natural to wonder whether the same option exists for a young person in your family. The short answer is that it doesn't, not legally in the UK. Wegovy's MHRA authorisation explicitly covers adults (people aged 18 and over) and that boundary exists for good reason. Regulatory agencies require separate clinical evidence in younger age groups before granting a licence, because adolescent physiology, development and psychological relationship with food all differ meaningfully from those of adults.

What's happened in the United States is relevant context, not a shortcut. The FDA approved semaglutide for adolescents aged 12 and over with obesity in late 2022, based on the STEP TEENS trial, which found around 16% average body-weight reduction over 68 weeks in that age group. But the FDA and the MHRA are separate regulators. A US approval does not make a medicine legal to prescribe in the UK, and the position for under-18s in the UK remains that no authorised indication exists. Anyone offering Wegovy to a British teenager through an online platform is operating outside the law and outside safe clinical practice.

A question our prescribers hear most weeks is whether a young person just a few months from their eighteenth birthday might qualify. The answer is still no until that birthday passes, and even then suitability is a clinical judgement, not a formality. You can find more on the Wegovy treatment overview for what licensed adult use involves.

What we know from the evidence, and what remains genuinely uncertain for this age group

The STEP TEENS data, published in the New England Journal of Medicine, showed meaningful weight reduction in 12-to-17-year-olds, alongside improvements in cardiometabolic markers. Side effects mirrored the adult profile, predominantly gastrointestinal, most noticeable early in treatment. That is encouraging science. What it is not is a UK licence, and NICE has not appraised semaglutide for adolescent weight management; no NICE technology appraisal covers this group.

There are also questions the trials haven't fully settled. Long-term effects on bone density, growth trajectories and pubertal development in younger adolescents are still being studied. Mental health and eating-behaviour effects in a population already at elevated risk of disordered eating require careful monitoring. The NHS medicines page for semaglutide reflects the adult licensed indication; it does not extend guidance to teenagers. For families, the honest framing is: the early evidence is promising, the safety picture in young people is less mature than in adults, and the UK regulatory system has not yet reached a decision on this age group.

If your teenager's weight is affecting their health, the right path is through their GP, who can refer to a paediatric specialist weight management team. These services exist, they are staffed by clinicians who understand adolescent health holistically, and they are the appropriate environment for any discussion of pharmacological treatment in young people. Explore what licensed weight-loss treatment looks like for adults, so you understand how that landscape is structured when the time comes.

What happens when a teenager turns 18, and how the adult process works

Once a young person reaches 18, the adult licence applies. At that point, you may also find it useful to read about whether teens can take Wegovy and how the eligibility rules change once someone reaches adulthood. Semaglutide (Wegovy) becomes a legal option if they meet the clinical criteria: a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure, high cholesterol or prediabetes, and there is separate guidance covering using Wegovy for type 2 diabetes where that condition is part of the picture. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Meeting the BMI threshold alone is not enough, a prescriber reviews the full clinical picture, including medical history, any medicines already being taken, and whether the timing is appropriate.

For an 18-year-old who has already been seen by a paediatric team, that background information is genuinely valuable to share at consultation. It means the prescriber has context rather than starting from zero. The cost of private Wegovy treatment is worth understanding early, and so is the difference between NHS and private routes, NICE's appraisal TA875 sets out the criteria for NHS access, which require specialist weight management services and carry waiting lists.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it arrives. For anyone who has just turned 18 and is considering treatment, that process begins with a free consultation, with no obligation and no automatic approval, suitability is always a clinical decision. If questions come up along the way, our team is reachable through our contact page. You can also read more about accessing Wegovy online as a young adult in the UK once the adult licence applies.